Salman Razvi
Overview
Explore the profile of Salman Razvi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
2681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baretella O, Blum M, Abolhassani N, Alwan H, Wildisen L, Del Giovane C, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39667018
Context: Subclinical thyroid dysfunction (ScTD) comprising subclinical hypothyroidism (SHypo) and subclinical hyperthyroidism (SHyper) has been associated with increased risk for cardiovascular events. Objective: To assess associations between ScTD and cardiovascular...
2.
Gad H, Tee S, Boot C, James A, Razvi S, Mamoojee Y
Clin Endocrinol (Oxf)
. 2024 Oct;
102(1):62-66.
PMID: 39351846
No abstract available.
3.
Razvi S, Nicodemus N, Ratnasingam J, Arundhati D, Soh W, Kunavisarut T, et al.
Curr Med Res Opin
. 2024 Aug;
40(9):1533-1536.
PMID: 39104288
Levothyroxine (LT4), being "narrow therapeutic index" drug, may lead to significant fluctuations in thyroid stimulating hormone (TSH) levels. Such fluctuations can result in clinically noteworthy disruptions in thyroid function and...
4.
Holley M, Razvi S, Farooq M, Dew R, Maxwell I, Wilkes S
Syst Rev
. 2024 May;
13(1):123.
PMID: 38720372
Background: Thyroid dysfunction is common in older people, with females at higher risk. Evidence suggests that thyroid-stimulating hormone (TSH) levels naturally increase with age. However, as uniform serum TSH reference...
5.
6.
Holley M, Razvi S, Dew R, Maxwell I, Wilkes S
Thyroid Res
. 2023 Nov;
16(1):43.
PMID: 37953303
Background: Subclinical hypothyroidism is diagnosed when serum thyroid stimulating hormone levels are higher whilst free thyroxine levels remain within their respective reference ranges. These reference ranges are uniformly applied in...
7.
Morton D, Vennart N, Slinger H, Gannon M, Razvi S, Bartholomew P
Nucl Med Commun
. 2023 Oct;
45(2):108-114.
PMID: 37901928
Objectives: To measure the absorbed dose to the thyroid in patients injected with 123 I-Ioflupane where the thyroid was not blocked with prophylaxis to investigate whether thyroid blocking should be...
8.
9.
Xu Y, Derakhshan A, Hysaj O, Wildisen L, Ittermann T, Pingitore A, et al.
Lancet Diabetes Endocrinol
. 2023 Sep;
11(10):743-754.
PMID: 37696273
Background: Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT) are statistically defined by the 2·5-97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define...
10.
Lane L, Cheetham T, Razvi S, Allinson K, Pearce S
Eur J Endocrinol
. 2023 Aug;
189(2):208-216.
PMID: 37536284
Objective: The specific mechanisms driving autoimmunity in Graves' disease (GD) remain largely unknown. Kappa-deleting recombination excision circles (KRECs) are circular DNA molecules generated during B cell maturation in the bone...